GlaxoSmithKline (GSK) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BofA/Merrill Lynch Downgrades GlaxoSmithKline (GSK) to Neutral
October 26, 2017 4:42 AM EDTBofA/Merrill Lynch downgraded GlaxoSmithKline (NYSE: GSK) from Buy to Neutral.
Analyst Graham Parry says the valuation is not demanding and sees growing uncertainties likely capping P/E recovery into 2018 stemming from margin pressure and consensus EPS reductions on Advair generics... More
